• 作者：E. Bravo Ruiz ; ^{ebravo2@telefonica.net} ; M. Vega de Cé ; niga ; M. Izagirre Loroñ ; o ; C. Casco Aguilar ; L. Estallo Laliena ; Á ; . Barba Vé ; lez
• 关键词：Antiagregantes ; Arteriosclerosis ; Enfermedad arterial perifé ; rica ; Estatinas ; Factores de riesgo cardiovascular ; Profilaxis secundaria
• 刊名：Angiolog铆a
• 出版年：2010
• 期刊代码：pca50_00033170
• 类别：med
• 出版时间：January-February 2010
• 卷：62
• 期：1
• 页码：3-8
• 文件大小：96 K

Objectives

We assess the prevalence of classic cardiovascular risk factors (CVRF) in patients with chronic lower limb ischaemia (CLLI) on their admission to a Vascular Surgery Unit. We analyse their control and treatment at baseline and after the first years of follow up.

Material and methods

A retrospective study, including patients with an initial diagnosis of CLLI in 2005鈥?006. We recorded: CVRF and their treatment, analytical parameters, and cardiovascular events and treatment after 3鈥? years of follow up. Statistical analysis performed were, Student t, Chi-squared and McNemar tests.

Results

The prevalence of active smoking, arterial hypertension, diabetes mellitus and dyslipaemia referred to by the patients was 45%(n = 91), 59.4%(n = 120), 35.6%(n = 72) and 35.6%(n = 72) respectively. We diagnosed an additional, three hypertensions, one diabetes and 72 hypercholesterolaemias in our baseline study. There was poor blood glucose control (HbA1c 鈮?7%) in 60%of the diabetics. Initially only 42.6%of patients received antiplatelet or anticoagulant treatment, 33.7%(n = 68) statins, and 85%(n = 102) of hypertensive patients received hypotensive drugs. After 28.6 卤 11.9 (1鈥?0.3) months, there was a reduction in active smoking to 30.8%(n = 62) (p < 0.0001), and an increase in antiplatelet or anticoagulant to 96%(n = 194) (p < 0.0001), statins to 60,9%(n = 123) (p < 0.0001) and hypotensives 100%(n = 123) (p < 0.0001). During this time, 19 (9.4%) had suffered coronary and 13 (6,4%) cerebrovascular events.

Conclusions

The prevalence of CVRF in patients with CLLI is high, often under-diagnosed, and their baseline treatment is deficient. We achieved satisfactory management, although not optimal, of CVRF in the first years of follow up, basically due to role of the vascular surgeon in the treatment and secondary prophylaxis of these patients.